Matches in SemOpenAlex for { <https://semopenalex.org/work/W2793859003> ?p ?o ?g. }
- W2793859003 abstract "Cholangiocarcinoma (CC) is the second most common primary hepatic malignancy. CC treatment options are very limited especially for patients with distant metastasis. Kangai 1 C-terminal interacting tetraspanin (KITENIN) is highly expressed in numerous cancers, but the role of KITENIN in CC remains unknown. Here, we have investigated for the first time the function of KITENIN in human CC cell lines (TFK-1, SZ-1), tissues and a CC mouse model (Alb-Cre/LSL-KRASG12D/p53L/L). KITENIN was expressed in 92.2% of human CC tissues, in murine CC samples and also in human CC cell lines. Knockdown of KITENIN by small interfering RNA (siRNA) effectively reduced proliferation, migration, invasion and colony formation in both intra- and extra-hepatic CC cells. The expression of epithelial-mesenchymal transition (EMT) markers like N-cadherin, Vimentin, Snail and Slug were suppressed in KITENIN knockdown CC cells. Our results indicate that KITENIN is crucial for cholangiocarcinogenesis and it might become a potential therapeutic target for human CC treatment." @default.
- W2793859003 created "2018-03-29" @default.
- W2793859003 creator A5002637074 @default.
- W2793859003 creator A5003141121 @default.
- W2793859003 creator A5003401938 @default.
- W2793859003 creator A5008171524 @default.
- W2793859003 creator A5016023158 @default.
- W2793859003 creator A5017432472 @default.
- W2793859003 creator A5019014290 @default.
- W2793859003 creator A5020099143 @default.
- W2793859003 creator A5023421590 @default.
- W2793859003 creator A5026070107 @default.
- W2793859003 creator A5027965195 @default.
- W2793859003 creator A5056667390 @default.
- W2793859003 creator A5064904760 @default.
- W2793859003 creator A5074229451 @default.
- W2793859003 creator A5082265323 @default.
- W2793859003 date "2018-03-01" @default.
- W2793859003 modified "2023-10-13" @default.
- W2793859003 title "Silencing of Kangai 1 C-terminal interacting tetraspanin suppresses progression of cholangiocarcinoma" @default.
- W2793859003 cites W1487355433 @default.
- W2793859003 cites W1711861384 @default.
- W2793859003 cites W1804903768 @default.
- W2793859003 cites W1863247901 @default.
- W2793859003 cites W1920712310 @default.
- W2793859003 cites W1934580930 @default.
- W2793859003 cites W1964081206 @default.
- W2793859003 cites W1973048052 @default.
- W2793859003 cites W2000086834 @default.
- W2793859003 cites W2009550277 @default.
- W2793859003 cites W2017767253 @default.
- W2793859003 cites W2026176112 @default.
- W2793859003 cites W2066550173 @default.
- W2793859003 cites W2073047578 @default.
- W2793859003 cites W2077629355 @default.
- W2793859003 cites W2090658591 @default.
- W2793859003 cites W2094465595 @default.
- W2793859003 cites W2095330969 @default.
- W2793859003 cites W2096778246 @default.
- W2793859003 cites W2105772211 @default.
- W2793859003 cites W2110999558 @default.
- W2793859003 cites W2115261608 @default.
- W2793859003 cites W2118930908 @default.
- W2793859003 cites W2121493672 @default.
- W2793859003 cites W2126496357 @default.
- W2793859003 cites W2139568990 @default.
- W2793859003 cites W2145608596 @default.
- W2793859003 cites W2150642877 @default.
- W2793859003 cites W2169988575 @default.
- W2793859003 cites W2226884398 @default.
- W2793859003 cites W2291204448 @default.
- W2793859003 cites W2337387091 @default.
- W2793859003 cites W2521507459 @default.
- W2793859003 cites W2524927879 @default.
- W2793859003 cites W2550448269 @default.
- W2793859003 cites W2557672556 @default.
- W2793859003 doi "https://doi.org/10.1016/j.yexcr.2018.01.028" @default.
- W2793859003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29366806" @default.
- W2793859003 hasPublicationYear "2018" @default.
- W2793859003 type Work @default.
- W2793859003 sameAs 2793859003 @default.
- W2793859003 citedByCount "1" @default.
- W2793859003 countsByYear W27938590032021 @default.
- W2793859003 crossrefType "journal-article" @default.
- W2793859003 hasAuthorship W2793859003A5002637074 @default.
- W2793859003 hasAuthorship W2793859003A5003141121 @default.
- W2793859003 hasAuthorship W2793859003A5003401938 @default.
- W2793859003 hasAuthorship W2793859003A5008171524 @default.
- W2793859003 hasAuthorship W2793859003A5016023158 @default.
- W2793859003 hasAuthorship W2793859003A5017432472 @default.
- W2793859003 hasAuthorship W2793859003A5019014290 @default.
- W2793859003 hasAuthorship W2793859003A5020099143 @default.
- W2793859003 hasAuthorship W2793859003A5023421590 @default.
- W2793859003 hasAuthorship W2793859003A5026070107 @default.
- W2793859003 hasAuthorship W2793859003A5027965195 @default.
- W2793859003 hasAuthorship W2793859003A5056667390 @default.
- W2793859003 hasAuthorship W2793859003A5064904760 @default.
- W2793859003 hasAuthorship W2793859003A5074229451 @default.
- W2793859003 hasAuthorship W2793859003A5082265323 @default.
- W2793859003 hasConcept C104317684 @default.
- W2793859003 hasConcept C119056186 @default.
- W2793859003 hasConcept C147447768 @default.
- W2793859003 hasConcept C1491633281 @default.
- W2793859003 hasConcept C153911025 @default.
- W2793859003 hasConcept C173396325 @default.
- W2793859003 hasConcept C203014093 @default.
- W2793859003 hasConcept C204232928 @default.
- W2793859003 hasConcept C22615655 @default.
- W2793859003 hasConcept C2777208748 @default.
- W2793859003 hasConcept C502942594 @default.
- W2793859003 hasConcept C54009773 @default.
- W2793859003 hasConcept C54355233 @default.
- W2793859003 hasConcept C55493867 @default.
- W2793859003 hasConcept C81885089 @default.
- W2793859003 hasConcept C86803240 @default.
- W2793859003 hasConceptScore W2793859003C104317684 @default.
- W2793859003 hasConceptScore W2793859003C119056186 @default.
- W2793859003 hasConceptScore W2793859003C147447768 @default.
- W2793859003 hasConceptScore W2793859003C1491633281 @default.
- W2793859003 hasConceptScore W2793859003C153911025 @default.